Merck & Co., Inc. business relationships

“Koselugo is part of a collaboration with AstraZeneca.” SEC filing

“(11) Commercialized under a worldwide collaboration with Bayer AG.” SEC filing

“Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol-Myers Squibb Company (BMS).” SEC filing

“The application is based on data from the Phase 3 KEYNOTE-905 trial conducted in collaboration with Pfizer and Astellas.” SEC filing

“...hepatitis B vaccine ( Recombivax HB , Hepatitis B Vaccine [Recombinant]) and, subject to a collaboration agreement with Sanofi Pasteur MSD, co-promotes a hexavalent vaccine that includes a hepatitis B component ( Vaxelis, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus...” SEC filing

“The Company's customers with the largest accounts receivable balances are: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., which represented approximately 22 %, 21 % and 13 %, respectively, of total accounts receivable at December 31, 2025.” SEC filing

“The Company's customers with the largest accounts receivable balances are: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., which represented approximately 22 %, 21 % and 13 %, respectively, of total accounts receivable at December 31, 2025.” SEC filing

“Intismeran autogene is being developed as part of a collaboration with Moderna, Inc.” SEC filing

“The Company's customers with the largest accounts receivable balances are: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., which represented approximately 22 %, 21 % and 13 %, respectively, of total accounts receivable at December 31, 2025.” SEC filing

“License-Related Payments - At December 31, 2025, the Company has accrued liabilities for contingent sales-based milestone payments of $890 million related to a license agreement with Alteogen Inc. where payment is dependent upon the achievement of the corresponding milestone.” SEC filing

“(a) Other revenues include royalties and alliance-related revenues for products not sold by our regional commercial organizations, including royalties received from Merck on Winrevair *.” SEC filing

“Reblozyl is the subject of a global licensing agreement pursuant to which we pay tiered royalties to Merck ranging from 20% to 24% of net sales, which are included in Cost of products sold.” SEC filing

“BMS receives royalties from Merck equal to 22 % of net sales.” SEC filing

“BMS and Ono are parties to a global patent license agreement with Merck related to Merck's PD-1 antibody Keytruda *.” SEC filing

“(1) For additional information regarding our collaborations with Merck, Arcellx and Arcus, see Note 7.” SEC filing

“In September 2023, we entered into a collaboration with Merck KGaA, Darmstadt, Germany.” SEC filing

“vaccine (developed and distributed in partnership with Merck & Co., Inc.) was approved in 2016 by the EC and is distributed in” SEC filing

“• Other agreements that Organon entered into with Merck include the Intellectual Property License Agreements and Regulatory Agreements.” SEC filing

“• Manufacturing and Supply Agreements - Merck and Organon and/or their applicable affiliates entered into a number of manufacturing and supply agreements pursuant to which the relevant Merck entity (a) manufactures and supplies certain active pharmaceutical ingredients for the relevant Organon entit...” SEC filing

“...and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird b...” SEC filing

“Absci has had a track record of partnerships with leading biopharmaceutical companies including Merck, AstraZeneca, Almirall and others.” SEC filing

“Pursuant to our collaboration and license agreement with Merck, we exclusively licensed to Merck a monospecific antibody targeting ILT4 (MK-4830), which Merck advanced in a Phase 2 clinical trial.” SEC filing

“In April 2014, we entered into a collaboration and license agreement with Merck to discover and optimize fully human antibodies against two undisclosed immunotherapy targets.” SEC filing

“...taking into account our obligations under the Ligand Purchase Agreement, XOMA Royalty Purchase Agreement and the recent status of our collaboration agreements, we remain eligible to receive up to approximately $49.4 million in potential development, regulatory, and commercial milestones from Merck.” SEC filing

“Amendment No. 2 to Clinical Trial Collaboration and Supply Agreement entered into as of July 24, 2018 between the Registrant and Merck Sharp & Dohme B.V.” SEC filing

“Pursuant to this collaboration, Merck is sponsoring KEYMAKER-U03 (a phase 1/2 trial evaluating zanzalintinib in combination with WELIREG® (belzutifan), Merck's oral HIF-2α inhibitor, in RCC), LITESPARK-033 (a phase 3 trial evaluating zanzalintinib in combination with WELIREG versus cabozantinib in f...” SEC filing

“Glass) as well as a select group of chemicals suppliers who range from large traditional companies such as Merck and Gentex to a few” SEC filing

“...programs, including BMS-986442 (Bristol Myers Squibb), AGEN2373 (Gilead), INCAGN2385 and INCAGN2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen Pharma) (collectively referred as "Agenus Partnered Programs"), and (ii) a synthetic 2.625 % royalty on future global net sales of Agenus' novel immuno-...” SEC filing

“In September 2022, Merck exercised its option for personalized cancer vaccines (PCVs), including mRNA-4157, pursuant to the terms of our existing PCV Collaboration and License Agreement with Merck, which was amended and restated in 2018 (PCV Agreement, also referred to as the INT Agreement).” SEC filing

“We are developing mRNA-4157 in collaboration with Merck.” SEC filing

“KEYNOTE D58 was designed and is being conducted as part of a clinical collaboration between Novocure and MSD, a tradename of Merck & Co., Inc. KEYNOTE D58 is currently open and enrolling, and we anticipate completing enrollment by the end of 2026.” SEC filing

“...Sanofi of $12.5 million made in 2023 pursuant to the Sanofi In-License Agreement, which was triggered as a result of the Merck Agreement, and lower costs related to Somatrogon (hGH-CTP) following the closure of open-label extension studies in countries where it has received marketing authorization.” SEC filing

“On January 7, 2025, ModeX announced the dosing of the first participant in a Phase 1 study for an EBV vaccine candidate being developed in collaboration with Merck.” SEC filing

“Certain of the rights subject to the license provided by us under the Merck Agreement were obtained by us from Sanofi pursuant to that certain License Agreement entered into as of July 1, 2021 ("Sanofi In-License Agreement") between us and Sanofi, a French corporation ("Sanofi"), and a portion of th...” SEC filing

“collaboration with Merck KGaA, Darmstadt, Germany.” SEC filing

“...ing solutions and the data generated by our multi-omic technology platform provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.” SEC filing

“This addresses a significant supply challenge: TICE BCG (Merck) has been the sole supplier of BCG product in the U.S. since 2012, and rationing has been ongoing since 2019.” SEC filing

“We are continuing our oncology clinical collaboration with Merck KGaA to evaluate the maintenance regimen of NKTR-255 in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma in the Phase II JAVELIN Bladder Medley study.” SEC filing

“In 2023, UDC Ireland entered into a Patent Sale and License Agreement with Merck KGaA.” SEC filing

“With respect to ALTO-202, as of December 31, 2025, we in-licensed from Cerecor one issued U.S. patent (owned by Merck and licensed to Cerecor) with claims directed to the composition of matter (ALTO-202 compound), which is expected to expire in 2026.” SEC filing

“We also in-licensed from Cerecor (co-owned with Merck) four issued U.S. patents and nine foreign issued patents or pending applications in Australia, Canada, China, Germany, Spain, France, India, United Kingdom, and Italy, with claims directed to composition of matter (polymorphic forms of ALTO-202)...” SEC filing

“as pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.) and retifanlimab, an immune checkpoint inhibitor manufactured” SEC filing

“Our OncoCompass ™ Target was selected in our companion diagnostics ("CDx") collaboration with Merck for the MET inhibitor tepotinib for the China market.” SEC filing

“as well as licensing agreements with Merck (MSD), Genentech and others.” SEC filing

“In September 2025, the Company out-licensed its vaccine candidate EVX- B3 to MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) as per the option and license agreement entered between the two companies in September 2024.” SEC filing

“We have in the period ended December 31, 2025, generated revenues $7.5 million primarily from our license agreement with Merck Sharpe Dome (MSD).” SEC filing

“Our operations have been funded primarily through equity financings, convertible debt, and private and governmental grants, and, most recently our partnership with Merck.” SEC filing

“...Agreement by and among Evaxion Biotech A/S, MSD International GmbH and MSD International Business GmbH, subsidiaries of Merck & Co., Inc., (known collectively as MSD outside the United States and Canada) (Incorporate by Reference to Exhibit 99.2 to Form 6-K filed with the Commission on October 25, 2...” SEC filing

“Exclusive Collaboration and License Agreement, by and between Merck Sharp & Dohme Corp. and Foghorn Therapeutics Inc., dated as of July 2, 2020 (Incorporated by reference to Exhibit 10.3 to the Registrant's Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 2, 202...” SEC filing

“Our pharmaceutical and biotechnology customers include companies and research laboratories such as Abbott, Amgen, AstraZeneca, Bayer, Glaxo Smith Kline, Johnson & Johnson, Merck, Novartis, Pfizer and Regeneron.” SEC filing

“In June 2024, Immutep entered into its third and most important collaboration with Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) for the registrational Phase III trial in non-small cell lung cancer called TACTI-004.” SEC filing

“In November 2022, Immutep signed a new Clinical Trial Collaboration and Supply Agreement with Merck KGaA and Pfizer to conduct the INSIGHT-005 trial.” SEC filing

“DNAtrix's DNX-2401, an oncolytic immunotherapy, has completed enrolment in a Phase 2 clinical trial in collaboration with Merck which evaluated the efficacy and safety of DNX-2401 in combination with pembrolizumab (Keytruda®), Merck's anti-PD-1 therapy.” SEC filing

“On September 13, 2022, we entered into a Clinical Trial Collaboration and Supply Agreement ("CTCSA") with Merck (known as MSD outside the United States and Canada) to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, in the ongoing Pha...” SEC filing

“...for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company ("BMS"), Eli Lilly, Merck, Novartis Pharmaceuticals Corporation ("Novartis"), Pfizer, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme ("Sanofi") and Roche.” SEC filing

“Our total revenue to date has been generated principally from our collaboration and license agreements with BMS, Merck, Astellas, Vaxcyte, Ipsen, EMD Serono, BioNova, and Tasly, and to a lesser extent, from manufacturing, supply and services and materials we provide to our collaborators.” SEC filing

“Our research collaborations with Merck, BMS, and EMD Serono all resulted in development candidate molecules that entered clinical development.” SEC filing

“2020 Research and License Agreement with Merck” SEC filing

“...), GlaxoSmithKline Intellectual Property Development Limited ("GSK"), Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo"), J&J, Merck Sharp & Dohme Research GmbH ("Merck"), primarily related to legacy platform collaboration agreements, as well as from BeOne related to our zanidatamab collaboration agreement...” SEC filing

“| | ● | | In July 2021, we entered into clinical collaboration with Merck, a leader in immuno-oncology.” SEC filing

“These companies include many of our large innovator and generic pharmaceutical customers, such as Merck, GSK, Novartis, Pfizer Inc., Bristol-Myers Squibb, Kyorin Pharmaceutical Corporation, and Teva Pharmaceuticals, which have significant internal research and development efforts directed at develop...” SEC filing

“The increase was primarily due to $34.0 million higher revenue from our licensing agreements with Merck entered into during the second and fourth quarters of 2025, and $3.3 million higher revenue from existing and legacy collaboration agreements.” SEC filing

“In addition, some of our agreements, including the agreements with GlaxoSmithKline plc ("GSK"), Merck Sharp & Dohme ("Merck"), Novartis Pharma AG ("Novartis"), Nestlé Health Science ("Nestlé"), Aldevro n LLC, Roche Sequencing Solutions, Inc., Crosswalk Therapeutics and Alphazyme LLC, provide for mil...” SEC filing

“Aspects of this program were developed in collaboration with Merck, which is legally protecting the intellectual property of the collaboration” SEC filing

“of Merck Sharp and Dohme Corp. (MSD), has entered into a license agreement with Tel Hashomer Medical Research Infrastructure and Services” SEC filing

“In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of ibrexafungerp.” SEC filing

“Under the license arrangement, executed in May 2013, the Company exclusively licensed from Merck its rights to ibrexafungerp in the field of human health.” SEC filing

“We were dependent on Merck for the establishment of our intellectual property rights related to ibrexafungerp, and if Merck did not establish our intellectual property rights with sufficient scope to protect ibrexafungerp, we may have limited or no ability to assert intellectual property rights to i...” SEC filing

“...Sonelokimab ( " SLK ") , a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany ("MHKDG") and that has the potential, based on response levels seen in clinical trials, to...” SEC filing

“• we are substantially dependent on the success of our novel tri-specific Nanobody®, Sonelokimab ("SLK", also known as M1095/ALX 0761), which we license from Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany ("MHKDG");” SEC filing

“with unresectable or metastatic melanoma (in collaboration with Merck & Co.) or other” SEC filing

“During the collaboration, Merck developed sabirnetug, an ADDL antibody, and intellectual property related to sabirnetug was filed by Merck.” SEC filing

“...are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company ("BMS"), Merck, Pfizer in partnership with Merck KGaA, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme ("Sanofi") and Roche.” SEC filing

“Merck has the right to terminate the Merck License Agreement immediately if we commence any interference or opposition proceeding or other challenge to the validity or enforceability of any Merck patent licensed to us under the Merck License Agreement or if we otherwise oppose any extension of, or t...” SEC filing

“We have exclusively licensed three patent families from Merck covering composition of matter, process of preparation, and formulations of ruzasvir, a pan-genotypic NS5A inhibitor which we are combining with” SEC filing

“The Company initially in-licensed the compound from an affiliate of Merck & Co., Inc. in 2013.” SEC filing

“The previously completed MM-001 Phase 1-2 trials were conducted using MM-001 which had IFNa2b provided by Merck & Co. under a supply agreement, which is now terminated.” SEC filing

“In January 2020, pembrolizumab, sold by Merck, was approved by the FDA to treat high-risk BCG-unresponsive NMIBC as monotherapy based on the results of the KEYNOTE-057 Phase 2 clinical trial.” SEC filing

“While there are other options globally for BCG, none of the options are available in the United States, except for the TICE BCG strain manufactured by Merck.” SEC filing

“This work produced BNC210 and the alpha7 PAM program, which we licensed to Merck.” SEC filing

“Under the 2014 Merck License Agreement, Merck is responsible for using commercially reasonable efforts to develop, file for marketing authorization for and, following receipt thereof, to commercialize at least one product thereunder.” SEC filing

“The Merck collaboration includes two clinical-stage alpha7 receptor PAM candidates.” SEC filing

“Our information rights are limited, and we depend on Merck for updates concerning development, safety and regulatory matters.” SEC filing

“PPSV23, manufactured and marketed by Merck is the only pneumococcal polysaccharide vaccine widely available.” SEC filing

“...ions to develop companion diagnostic tests, that we have entered (for example, our strategic alliances with Moderna and Merck; and our collaborations with Tempus; Myriad; ClearNote Health, Inc.; Cancer Research UK, University College London, and the Francis Crick Institute (the TRACERx study); Insti...” SEC filing

“In December 2018, we, in collaboration with Merck, initiated a Phase 1/2 open-label, non-comparative, multicenter, multi-arm clinical trial of GPS in combination with pembrolizumab in patients with WT1-positive advanced cancers, including both hematologic malignancies and solid tumors.” SEC filing

“...check-point inhibitor (e.g., PD-1 inhibitor), we entered into a Clinical Trial Collaboration and Supply Agreement with Merck (known as MSD outside the United States and Canada), to assess the efficacy and safety of GPS in combination with Merck's anti-PD-1 therapy pembrolizumab with exploratory lon...” SEC filing

“Other companies with selective KRAS inhibitors include AstraZeneca (in collaboration with Usynova), BioNTech, Roche, Merck/Moderna, Boehringer and Gilead.” SEC filing

“On August 12, 2025, we announced a major new customer in the eye health sector, comparable in scale to Pfizer and Merck, who implemented SteraMist iHP at two facilities in under four months and placed open BIT Solution orders for 2026.” SEC filing

“We have worldwide, exclusive rights to atacicept from Ares, an affiliate of Merck, pursuant to a license agreement (Ares Agreement), which advanced atacicept in randomized, double-blind, placebo-controlled clinical trials for several autoimmune diseases in over 1,500 patients, in which it was well t...” SEC filing

“This is due to the completion of the amended collaboration agreement with Merck ended in May 2024.” SEC filing

“...mmercialized and/or are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company, Merck, Pfizer in partnership with Merck KGaA, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme and Roche.” SEC filing

“Merck KGaA Collaboration and License Agreement” SEC filing

“In addition to our internal discovery strategy, we also have discovery programs in collaboration with our partners, Merck KGaA and Roche.” SEC filing

“In the second quarter of 2024, we announced a clinical collaboration with Merck to supply KEYTRUDA ® for evaluation of its combination with CX-801 in the Phase 1 study.” SEC filing

“In 2019, as part of our IT-01 Study, we entered into a supply agreement with Merck to evaluate the combination of INT230-6 with Keytruda ® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid malignancies, including pancreatic, bile duct, squamous cell and non-MSI high colon c...” SEC filing

“...tumor indications, including, but not limited to, ivonescimab (Summit Therapeutics Inc.), pumitamig (co-developed by BioNTech SE and Bristol Myers Squibb), LM-299 (LaNova Medicines Ltd.; in-licensed by Merck), SSGJ-707 (3SBio Inc.; in-licensed by Pfizer), and CTX-10726 (Compass Therapeutics, Inc.).” SEC filing

“We have financed our working capital requirements primarily through private and public offerings of equity securities, cash received from BI, IMSCP, LG Chem, Ono, and Merck Sharp & Dohme Corp. under collaboration agreements, and borrowings under the Loan Agreement.” SEC filing

“Codexis, Inc. partnered with Tate & Lyle and Merck & Co., Inc. on different, highly” SEC filing

“Clinical collaboration with Merck” SEC filing

“and Asia, raised $100 million in equity, and set up partnerships with Merck, Fosun Pharma, Tasly Pharma, and Kalbe Pharma.” SEC filing

“The agreement does not provide Merck with any rights to MICVO outside of the collaboration study.” SEC filing

“In November 2024, we announced a Clinical Trial Collaboration and Supply Agreement with Merck & Co, Inc. or Merck (known as MSD outside of the United States and Canada), for a Pyxis Oncology-sponsored study of MICVO in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).” SEC filing

“...gulatory approvals for their anti-PD-1/PD-L1 antibodies, including AstraZeneca, BeiGene/Novartis, Bristol-Myers Squibb, Merck, Pfizer in partnership with Merck KGaA, Regeneron in partnership with Sanofi Genzyme and Roche/Genentech, and there are also many other anti-PD-1 and anti-PD-L1 antibodies in...” SEC filing

“...Pharmaceuticals Co. Ltd. (licensed to Shanghai Allist Pharmaceuticals), Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Merck, Sharpe & Dohme LLC, Roche/Genentech, Shanghai Junshi Biosciences Co., Ltd., Shanghai YingLi Pharmaceutical, Shouyao Holdings (Beijing) Co. Ltd. and Suzhou Zelgen Biopharmace...” SEC filing

“The FDA has authorized emergency use ("EUA") of oral molnupiravir (sold by Merck and Ridgeback).” SEC filing

“later sold to Merck Serono.” SEC filing

“In February 2025, we entered into a Distribution and Collaboration Agreement (the "Distribution Agreement") with Millipore S.A.S., a subsidiary of the Life Science business of Merck KGaA, Darmstadt, Germany, which operates in the U.S. as MilliporeSigma ("MilliporeSigma").” SEC filing

“For example, the current standard of care for NMIBC includes intravesical BCG TICE (manufactured by Merck & Co., Inc.).” SEC filing

“Research Collaboration and Option to License Agreement, effective as of May 24, 2017, by and between Synthetic Genomics, Inc. and Merck Sharp & Dohme Corp. (incorporated herein by reference to Exhibit 10.11 to the Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2019).” SEC filing

“Research Collaboration and Exclusive License Agreement with Merck” SEC filing

“Our existing collaborations with Merck and BMS are important to our business.” SEC filing

“...Phase III clinical studies globally, PF-08634404 (PF'4404 / SSGJ-707), which was licensed globally, ex-China by Pfizer Inc. in July 2025, LM-299, which was licensed globally by Merck & Co., Inc. in November 2024, and RC148, which was licensed outside of Greater China by AbbVie Inc. in January 2026.” SEC filing

“at Merck Research Laboratories, including external research, out-licensing regional deals, and academic alliances.” SEC filing

“With the exclusive global license agreement with Merck” SEC filing

“Based on this encouraging preclinical and human data, PDS0101 has been studied in multiple Phase 2 clinical trials in various HPV-related cancers; one sponsored by the Company in collaboration with Merck (VERSATILE-002) and” SEC filing

“Some of these therapies are manufactured and marketed by large pharmaceutical companies such as Johnson & Johnson, Gilead Sciences, Inc., Bayer Schering Pharma AG, GSK plc, and Merck, as well as a variety of large generic drug manufacturers.” SEC filing